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ABSTRACT
There are many unmet needs with current gastric acid suppression with proton pump inhibitors (PPIs). 
Recommended prescription of one standard morning dose for all patients and for all medical conditions must 
be scientifically inappropriate and far from individualized personal medicine. For several diseases, especially 
gastroesophageal reflux disease and Barrett esophagus, more intense, more prolonged diurnal acid suppression 
is indicated. Especially inhibition of nocturnal acid secretion with our current delayed-release PPIs turns out 
to be difficult. This overview summarizes the actual attempts to improve the control of acid secretion, which is 
necessary to adapt the degree of acid inhibition to the individual patient needs. To be discussed are: immediately 
release PPIs, extended PPI formulations, PPIs with a much longer half-life, potassium competitive acid blockers, 
gastrin antagonists, etc. Future studies have to proof that those novel drug approaches indeed contribute to 
reduce the unmet needs. 
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ABSTRAK
Pada saat ini banyak kebutuhan yang tidak terpenuhi dalam upaya menekan produksi asam lambung 
dengan menggunakan penghambat pompa proton. Rekomendasi pemberian satu dosis standar di pagi hari 
untuk semua pasien dan semua kondisi medis seharusnya merupakan hal yang tidak sesuai secara ilmiah dan 
jauh dari pemenuhan kebutuhan pasien secara individu. Untuk beberapa penyakit, terutama penyakit refluks 
gastroesofageal dan esofagus Barrett, diindikasikan dengan penggunaan supresi asam diurnal yang lebih 
intensif dan waktu kerja lebih panjang. Dengan obat penghambat pompa proton lepas lambat yang digunakan 
saat ini, inhibisi sekresi asam nokturnal dirasa sulit. Artikel ini merangkum usaha aktual untuk meningkatkan 
kontrol sekresi asam yang diperlukan untuk mengadaptasi tingkat inhibisi asam sesuai dengan kebutuhan pasien. 
Beberapa hal yang akan didiskusikan antara lain: penghambat pompa proton lepas langsung, penghambat 
pompa proton dengan formulasi ekstensi, penghambat pompa proton dengan waktu paruh yang jauh lebih 
panjang, penghambat asam kompetitif dengan kalium, antagonis gastrin, dan lain-lain. Studi selanjutnya perlu 
dilakukan untuk membuktikan bahwa pendekatan terhadap obat-obatan tersebut berkontribusi dalam mengurangi 
kebutuhan yang belum terpenuhi.
Kata kunci: sekresi asam, penghambat pompa proton, sekresi asam nokturnal
INTRODUCTION
Anti-acid secretory therapy has greatly advanced 
since the introduction of H2-receptor antagonist and 
especially proton pump inhibitors (PPIs). Yet there 
remain unmet needs, especially in the treatment 
of gastroesophageal reflux disease (GERD). This 
overview will discuss some of the possibilities that 
are being explored to remedy the unmet needs where 
an antisecretory treatment with rapid onset of action 
and sustained antisecretory effect would be desirable.1
TRADITIONAL DELAYED RELEASE PROTON PUMP 
INHIBITORS (DRPPIS)
The Traditional Proton Pump Inhibitors
Omeprazole, lansoprazole, pantoprazole, 
rebeprazole, esomeprazole are prodrugs and need to 
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be converted to be a sulfonamide form in the acid space 
of secretory canacilus. Activated PPIs then establish a 
covalent disulphide bond with cysteines of the proton 
pump, blocking the H/K exchange path. The speed of 
activation of a delayed release proton pump inhibitor 
(drPPI) in the acidic medium depends on the pKa, 
which varies between the various PPIs. Esomeprazole, 
the S-isomer of omeprazole, has an improved 
pharmacokinetic profile with higher bioavailability and 
less inter-individual variability.2 All drPPIs are acid 
labile and need to be protected from acid breakdown 
when passing the stomach through enteric coating. 
Another limitation of drPPIs is their short plasma 
half-life of about 1-1.5 hour, when compared to the 
half-life of activation and synthesis of H/K-ATPase 
of about 24-hour. 
All drPPIs have relatively slow onset of 
pharmacological action and may require several doses 
to achieve maximum acid suppression and symptom 
relief, possibly limiting their usefulness in on-demand 
treatment. The time of dosing and ingestion of meals 
may also influence the pharmacokinetics of drPPIs. 
Moreover they fail to provide full 24-hour suppression 
of gastric acid production because all allow nocturnal 
acid recovery, defined as a drop of intragastric pH under 
4 for more than 1-hour, even with twice-daily dosing.3
NOVEL DEVELOPMENT AND FUTURE EXPECTATIONS
New PPIs formulations, recently introduced in 
clinical practice or under development and new 
avenues such as competitive K antagonism or blockade 
of CCK2 receptors will be explored in this section. 
Immediate-release (Ir) Proton Pump Inhibitor or 
Ir-omeprazole
This formulation consists of pure, non enteric 
coated omeprazole powder along with sodium 
bicarbonate. The antisecretory effect of immediate 
release (ir)-omeprazole is quicker compared to drPPIs. 
The early increase in intragastric pH is likely due to 
the neutralizing effect of sodium bicarbonate, which 
may also accelerate and enhance the absorption of 
omeprazole, whose increased bioavailability may 
translate in more profound acid suppression. The 
rapid rise of intragastric pH may also facilitate gastrin 
release, enhancing activation proton pumps, available 
or inhibition. This new formulation provide sustained 
control of intragastric pH at steady and when dosed 
at bedtime, may be effective in improving control of 
nocturnal pH and treating night-time GERD.4-6
Extended Release Formulations of drPPIs 
Extended-release formulations may well become an 
important strategy to inhibit nocturnal acid recovery 
because of their controlled and sustained release.
AGN 201904 is the acid stable sodium salt of 
sulfonamide of omeprazole, designed to delay 
absorption and to prolong the plasma residence time 
and thereby increase the number of proton pumps that 
might be inhibited. The drug was shown to provide 
faster and more profound acid auppression, including 
the nocturnal period.7
TAK-390MR is an extended release version of 
dexlansoprazole with a dual-peaked pharmacokinetic 
profile. TAK-390MR has shown prolonged acid 
inhibition across all dose levels compared to the parent 
compound. The drug has been shown to be highly 
efficacious in inducing and maintaining healing of 
erosive esophagitis.8,9
Novel Proton Pump Inhibitors with Prolonged 
Half-Life
Tenatoprazole, unlike the traditional drPPIs, has 
an imidazopyridine backbone, which is responsible 
for the prolonged half-life of 7 to 8 hours. Also 
tenatoprazole is a prodrug (pKa 4.04), converted 
to the active sulfonamide by acid in the secretory 
canaliculus. The active species binds to luminqally 
accessible cysteine 813 and 822 of the pump, resulting 
in disulfide formation and blockage of the proton 
transport pathway. The increase of intragastric pH with 
tenatoprazole 40 mg daily up to 7 days is significantly 
higher compared to esomeprazole 40 mg. Particular 
the improvement of nocturnal acid secretory control 
is impressive.10,11 Tenatoprazole is a racemic mixture 
of two steroisomers, which derive from the chiral 
nature of the sulphur atom of the sulphinyl group. The 
bioavailability of S-tenatoprazole sodium salt hydrate 
is almost twice that of free S-tenatoprazole, which was 
selected for further development. So far no clinical 
trials are available.
Potassium-competitive Acid Blockers or Acid 
Pump Antagonists 
Acid pump antagonists (APAs) are potassium 
competitive inhibitors of H/K- ATPase, interfering with 
the potassium-binding region of the pump. Potassium-
competitive acid blockers (PCABs) are lipophilic weak 
bases with high pKa values and stable at low pH. 
PCABs with a pKa of 6 would theoretically be expected 
to be 100,000-fold higher in the acid space of the 
parietal cell than in the plasma. On entering the acidic 
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space, PCABs are instantly protonated and compete 
for the potassium-binding site of the pump, resulting 
in more rapid and stronger acid inhibition compared 
to drPPIs. Because of these characteristics, PCABs 
were considered superior for on-demand therapy. 
Unfortunately, superiority to drPPIs (esomeprazole) 
with AZD0865 could not be seen, neither in erosive-, 
nor in non-erosive GERD.12,13 In addition, transient, 
dose-related rise in transaminases was observed. It is 
currently impossible to predict whether this class of 
drugs will ever become available for clinical use.
Gastrin (CCK2) Antagonists
Gastrin is a major endocrine regulator of acid 
secretion, thought to be responsible for up to 90% 
of postprandial acid secretion. Gastrin receptors are 
identical to CCK2-receptors, present on parietal and 
enterochromaffin-like cells. Selective CCK2-receptor 
antagonists offer a potential approach to regulate acid 
production. Compounds like itriglumide have been 
shown to inhibit gastrin-stimulated acid secretion in a 
dose dependent manner. Theoretically, CCK2 receptor 
antagonist could antagonize the effects of drPPI-
induced hypergastrinemia on parietal and ECL-cell 
hyperplasia.14 Whether CCK2-receptor antagonists will 
ultimately become available for the treatment of acid 
and gastrin-related disorders is uncertain at present.
CONCLUSION
Obviously the synthesis of drPPIs has been a major 
breakthrough in the treatment of acid related disorders. 
Yet over the years limitations and shortcomings were 
recognized, justifying the search for novel possibilities 
for full control of acid secretion. Several of those novel 
pathways were alluded above. Unfortunately progress 
has been slow and often disappointing and frustrating. 
This explains to some extent the catastrophic and 
rapid lost of interest of the biopharmaceutical industry 
for acid related disorders and gastroenterology in 
general. The impact of acid related disorders in clinical 
medicine is substantial and will in all probability 
increase worldwide this by itself justifies more 
interest from the biomedical industry. Hopefully 
some of the new avenues will mature and ultimately 
become clinically available for improved care of the 
gastrointestinal patients.
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